Wikipedia -WSS

Wikipedia

author：explore 2025-09-29 01:36:55 - browse：2

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The strategy behind pharma's lawsuits over drug pricing reform

explore

focus

WSS

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Physician subsidies by hospitals soar in wake of No Surprises Act

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Traditional Chinese medicine benefits explored in new JAMA study

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

leisure time

Wikipedia

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Senate panel to vote on hospitals, PBMs, prisoner care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why Sanofi got shellacked over its spinoff

As demand for Covid shots wanes, Moderna seeks its next success

Why we need to separate burnout from moral injury in health care

Duchenne breakthrough therapy leaves behind pioneering families

Disclosing genetic information: not as worrisome as once feared

Anesthesiologist group: stop taking Ozempic before surgery

FDA has safety concerns on CRISPR

Wikipedia

Diversifying clinical trials isn't enough to close racial gaps: study

Traditional Chinese medicine benefits explored in new JAMA study

The FDA weighs the risks of candy

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Testing for cancer recurrence creates a new limbo for patients

Death of patient in Alzheimer’s trial raises question of possible risks

explore

hotspot

focus

leisure time